RESUMO
BACKGROUND: Acute enteropathy is a trigger of chronic gastrointestinal (GI) disease in humans. OBJECTIVE: To report the prevalence of and explore possible risk factors for signs of chronic GI disease in dogs after an episode of acute hemorrhagic diarrhea (AHD). ANIMALS: One hundred and fifty-one dogs, 80 dogs with a historical diagnosis of AHD, 71 control dogs with no history of AHD. METHODS: In this retrospective longitudinal study, data were collected from dogs with a historical diagnosis of AHD and healthy controls matched by breed, age and sex, aged between 1 year and 15 years of age, for which a follow-up of at least 12 months after enrolment was available. Dog owners responded to a questionnaire to determine the history of signs of chronic GI disease. RESULTS: There was a higher prevalence of signs of chronic GI disease in the dogs with a previous episode of AHD compared to control dogs (AHD 28%; controls 13%; P = .03; odds ratio = 2.57; confidence interval [CI] 95% 1.12-6.31) over a similar observation time (median 4 years; range, 1-12 years). CONCLUSIONS AND CLINICAL IMPORTANCE: Severe intestinal mucosal damage and associated barrier dysfunction might trigger chronic GI disease later in life.
Assuntos
Doenças do Cão , Animais , Diarreia/epidemiologia , Diarreia/veterinária , Doenças do Cão/epidemiologia , Doenças do Cão/etiologia , Cães , Hemorragia Gastrointestinal/veterinária , Estudos Longitudinais , Estudos RetrospectivosRESUMO
BACKGROUND: Despite limited evidence of efficacy, antibiotic treatment is still frequently prescribed in dogs with uncomplicated acute diarrhea (AD). OBJECTIVE: To assess whether amoxicillin-clavulanic acid has a clinical benefit, an effect on the fecal microbiome, and the proportion of amoxicillin-resistant Escherichia coli in dogs with AD. ANIMALS: Sixteen dogs with AD of <3 days duration. METHODS: Prospective, placebo-controlled, double-blinded study. Clinical scores were compared between client-owned dogs randomly assigned to an antibiotic (AG) or a placebo (PG) group. The intestinal microbiome was analyzed using quantitative PCR assays. Amoxicillin-resistant fecal E. coli were assessed semiquantitatively with microbiological methods. RESULTS: There was no difference in clinical recovery between treated dogs or controls (CADS index day 10: AG group median: 2 (range: 1-3; CI [1.4; 2.6]); PG group median: 1.6 (range: 1-3; CI [1.1; 2.4]); P > .99). All dogs gained normal clinical scores (CADS index ≤3) after 1 to 6 days (median 2 days) after presentation. There was no significant difference in the fecal dysbiosis index (during treatment: AG mean -2.6 (SD 3.0; CI [-5.1; 0.0]); PG mean -0.8 (SD 4.0; CI [-4.2; 2.5]; P > .99) or its bacterial taxa. The proportion of resistant fecal E. coli increased (to median: 100%; range: 35%-100%) during treatment with amoxicillin-clavulanic acid and was still increased (median: 10%; range 2%-67%) 3 weeks after treatment, both of which were significantly higher proportions than in the placebo group for both time points (during treatment AG median 100% versus PG median 0.2% (P < .001); after treatment AG median 10% versus PG median 0.0% (P = .002)). CONCLUSIONS AND CLINICAL IMPORTANCE: Our study suggests that treatment with amoxicillin-clavulanic acid confers no clinical benefit to dogs with AD, but predisposes the development of amoxicillin-resistant E. coli, which persist for as long as 3 weeks after treatment. These findings support international guideline recommendations that dogs with diarrhea should not be treated with antimicrobials unless there are signs of sepsis.
Assuntos
Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Diarreia/veterinária , Doenças do Cão/tratamento farmacológico , Escherichia coli/efeitos dos fármacos , Microbioma Gastrointestinal/efeitos dos fármacos , Amoxicilina/farmacologia , Animais , Antibacterianos/uso terapêutico , Diarreia/tratamento farmacológico , Doenças do Cão/microbiologia , Cães , Farmacorresistência Bacteriana/efeitos dos fármacos , Testes de Sensibilidade Microbiana/veterinária , Estudos ProspectivosRESUMO
BACKGROUND: Reticulocyte hemoglobin content provided by the Siemens ADVIA (CHr) is an established marker of iron deficiency. The IDEXX ProCyte Dx hematology analyzer now provides a similar variable, reticulocyte hemoglobin equivalent (RET-He). OBJECTIVES: The objective was to evaluate RET-He and its diagnostic utility in dogs, and to calculate a cutoff value for diagnosing iron-deficient erythropoiesis (IDE). Furthermore, the prevalence of RET-He values below this cutoff value was established. METHODS: One hundred and seventy-one CBCs of healthy dogs were used to establish a RI. Stability of RET-He was evaluated by repeated measurements over 48 hours (n = 10). The 25-run coefficient of variation (CV) was calculated, and correlation and bias between measurements of RET-He and CHr were assessed (n = 190). A cutoff value for diagnosing IDE was calculated. The utility of RET-He in the detection of IDE was evaluated in 123 dogs. The prevalence of low RET-He values was assessed retrospectively in a multicenter study (2012-2014) under participation of 7 veterinary clinics. RESULTS: Reticulocyte hemoglobin equivalent with an RI of 22.2 to 28.6 pg was statistically stable over 48 hours (P = .10). The CV was 1.8%. A fair correlation (ρ = 0.74) between RET-He and CHr with a small bias of -0.6 pg was found. The cutoff value for diagnosing IDE was 20.9 pg (sensitivity: 85%; specificity: 99%). The prevalence of RET-He values below 20.9 pg was 10.3% (1084/10,553 dogs). CONCLUSIONS: RET-He on the ProCyte Dx is a precise screening tool in dogs to detect iron-deficient erythropoiesis.
Assuntos
Anemia Ferropriva/veterinária , Doenças do Cão/sangue , Eritropoese , Hemoglobinas/metabolismo , Deficiências de Ferro , Reticulócitos/metabolismo , Anemia Ferropriva/sangue , Anemia Ferropriva/diagnóstico , Animais , Doenças do Cão/diagnóstico , Doenças do Cão/epidemiologia , Cães , Feminino , Ferro/sangue , Masculino , Valor Preditivo dos Testes , Prevalência , Estudos Prospectivos , Estudos RetrospectivosRESUMO
BACKGROUND: Reticulocyte hemoglobin content (RET-He) is a diagnostic marker for iron deficiency (ID) in people and dogs. OBJECTIVES: The aim of our study was to evaluate the clinical utility of RET-He in the diagnosis of different causes of iron-deficient erythropoiesis (IDE). METHODS: Canine CBCs were separated into 2 groups according to RET-He values, < 20.9 pg or ≥ 20.9 pg. Erythrocyte and reticulocyte variables were compared between dogs with decreased and normal RET-He values. Additional data for a subgroup of dogs were collected, and dogs with low RET-He values were categorized as having ID, inflammatory disorders (INFL), portosystemic shunt (PSS), miscellaneous diseases (MISC), or combinations of these diseases (ID+INFL, ID+PSS). Hematologic variables were compared between dogs of the different disease groups. RESULTS: Overall, 10.3% (1084/10,553) of canine CBCs showed decreased RET-He values. Significant differences between dogs with decreased and normal RET-He values were found for all erythrocyte and reticulocyte variables. The majority (68.9%, 747/1084) of dogs with low RET-He values was anemic; 28.9% (216/747) of those anemic dogs had microcytosis and hypochromasia. In the subgroup of dogs, 8.9% (205/2306) had low RET-He values. According to their diagnosed diseases, anemic dogs (138/205) could be categorized as ID (17/138; 12.3%), INFL (16/138; 11.6%), PSS (30/138; 21.7%), ID+INFL (63/138; 45.7%), ID+PSS (8/138; 5.8%), and MISC (4/138; 2.9%). Distribution in nonanemic dogs (67/205) was similar, except for a lower number of dogs with PSS. CONCLUSIONS: Low RET-He values indicate IDE even in dogs with other CBC variables within the RIs.
Assuntos
Anemia Ferropriva/veterinária , Doenças do Cão/sangue , Eritropoese , Hemoglobinas/análise , Reticulócitos/química , Anemia Ferropriva/sangue , Animais , Contagem de Células Sanguíneas/veterinária , Cães , Eritropoese/fisiologia , Feminino , Masculino , Estudos RetrospectivosRESUMO
In-house tests for the identification of faecal parvovirus antigen are now available. The majority of these are licensed for canine parvovirus only; but anecdotal information suggests that they will detect feline panleukopenia virus (FPV) as well. This prospective study was designed to compare five commercially available test systems. In total, 200 faecal samples from randomly selected healthy cats (148) and cats with diarrhoea (52) were tested and compared with the results of examination by electron microscopy. Ten cats were positive for FPV and all of these had diarrhoea. In-house canine parvovirus tests can be used to detect FPV. All tests were suitable to screen cats for faecal parvovirus excretion (positive predictive values for the Witness Parvo, the Snap Parvo, the SAS Parvo, the Fastest Parvo Strip, and the Speed Parvo were 100.0, 100.0, 57.1, 38.9, and 100%, respectively, negative predictive values for the Witness Parvo, the Snap Parvo, the SAS Parvo, the Fastest Parvo Strip, and the Speed Parvo were 97.4, 97.9, 98.9, 98.4, and 97.4%, respectively). In-house parvovirus tests may be positive up to 2 weeks after vaccination, and therefore, in recently vaccinated cats positive results do not necessarily mean infection.